Investment entity tied to Roivant (ROIV) director reports multi-day share sales

Rhea-AI Filing Summary

Roivant Sciences director-associated entity reports share sales. An investment entity, QVT Financial Investment Cayman Ltd., which is associated with director Keith S. Manchester, executed several indirect open-market sales of Roivant Sciences common shares between February 11 and 13, 2026.

Transactions included sales of 425,000 shares at $26.67, 150,000 shares at $26.72, 275,000 shares at $26.76, 150,784 shares at $26.49, and 225,000 shares at $26.50. Following these trades, QVT Financial Investment Cayman Ltd. is reported as indirectly holding 15,127,329 common shares.

The filing notes that Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MANCHESTER KEITH S

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/11/2026		S		425,000	D	$26.67	15,928,113	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	02/12/2026		S		150,000	D	$26.72	15,778,113	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	02/12/2026		S		275,000	D	$26.76	15,503,113	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	02/13/2026		S		150,784	D	$26.49	15,352,329	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	02/13/2026		S		225,000	D	$26.5	15,127,329	I(1)	Held by QVT Financial Investment Cayman Ltd.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

	/s/ Keith Manchester	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Roivant Sciences Ltd. (ROIV) disclose?

Roivant Sciences disclosed indirect open-market sales of common shares by QVT Financial Investment Cayman Ltd. between February 11 and 13, 2026. These trades were reported on a Form 4 filed by director Keith S. Manchester in his capacity as an associated reporting person.

How many Roivant Sciences common shares were sold in the reported Form 4?

The Form 4 lists multiple open-market sales: 425,000, 150,000, 275,000, 150,784, and 225,000 Roivant common shares. Each trade was executed at prices between $26.49 and $26.76 per share, reflecting several sizable transactions over three consecutive trading days.

Who actually executed the Roivant Sciences (ROIV) share sales?

The sales were executed by QVT Financial Investment Cayman Ltd., which holds Roivant common shares. Director Keith S. Manchester is a shareholder of this entity, but the filing states he has no voting or investment control over it and reports the holdings as indirect.

What prices were received for the Roivant Sciences shares sold?

Reported sale prices ranged from $26.49 to $26.76 per Roivant Sciences common share. Individual transactions were executed at $26.49, $26.50, $26.67, $26.72, and $26.76, indicating sales clustered within a narrow price band during the three-day period.

How many Roivant Sciences shares remain held after these insider-related sales?

After the reported transactions, QVT Financial Investment Cayman Ltd. is shown as indirectly holding 15,127,329 Roivant Sciences common shares. This figure reflects the balance following the final sale reported on February 13, 2026, in the sequence of disclosed trades.

Does Keith S. Manchester claim beneficial ownership of the Roivant shares?

The filing states Manchester disclaims beneficial ownership of the Roivant common shares held by QVT Financial Investment Cayman Ltd., except to the extent of his pecuniary interest. It also specifies he has no voting or investment control over that investment entity’s holdings.